Actavis announces acquisition of Silom Medical for $100 million Actavis plc.

Actavis announces acquisition of Silom Medical for $100 million Actavis plc , a respected global specialty pharmaceutical firm today announced that it has acquired Silom Medical Organization, a privately held generic pharmaceutical company focused on advertising and developing therapies in Thailand, for approximately $100 million in money. The acquisition of Silom Medical instantly elevates Actavis right into a top-five position in the Thai generic pharmaceutical marketplace, with leading positions in the ophthalmic and respiratory therapeutic types and a solid cardiovascular franchise.’ Related StoriesCamels in Kenya infected by MERS virus, new research findsLuminex's NxTAG Respiratory Pathogen Panel receives CE-IVD markingAfter acute myocardial infarction, respiratory infection connected with increased threat of mortality Actavis markets approximately a dozen products through local distributors in Thailand presently, and has around nine additional items under registration.Discussion The main reason for the TREAT was to determine whether treatment of a minimal hemoglobin level with darbepoetin alfa would decrease the threat of death and main cardiovascular and renal events among patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. There is no factor in the overall rates of either the principal cardiovascular composite end point or the primary renal composite end stage by using the therapeutic strategy of increasing the hemoglobin level with darbepoetin alfa versus placebo . In this study involving 4038 sufferers assigned to a report group randomly, with 9941 patient-years of follow-up and with 1234 patients who acquired a composite final result of a cardiovascular event and 1270 individuals who had a composite outcome of a renal event, we found no general significant differences in the hazard prices for these clinically essential outcomes or in the rates of death, heart failing, myocardial infarction, admission for myocardial ischemia, or end-stage renal disease.

You may also like